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Abstract 
C-reactive protein (CRP) is a sensitive and specific marker of systemic inflammation in 
dogs, valuable for diagnosing and monitoring inflammatory diseases. The use of CRP in 
canine medicine has however been hampered by the lack of automated assays optimized 
for measuring CRP in this species. The need for improved CRP assays was the reason 
for initiating the current project, with the goal to generate automated, canine-specific 
CRP tests that could reliably measure serum CRP over the whole concentration range 
expected to occur in dogs. Two different assays were developed for this purpose. One 
was designed for routine diagnostic testing, and one was a high-sensitivity CRP test 
intended for research. Method validation studies were performed, demonstrating that 
both tests met the predefined quality criteria. Using the two novel CRP tests, it was 
possible to reliably measure serum CRP concentrations in the range of 0.5-1200 mg/l. 
After successful termination of the validation studies, the CRP assays were used in 
clinical research studies. C-reactive protein concentrations were measured in dogs with 
pyometra undergoing ovariohysterectomy, to evaluate how surgical treatment affected 
degree of systemic inflammation in these patients. Two other studies were performed to 
evaluate the usefulness of CRP as a diagnostic test. C-reactive protein concentration was 
found to discriminate well between dogs with suppurative arthritis and dogs with 
osteoarthritis, whereas measurement of CRP was not efficient for diagnosing late post-
operative bacterial infections after orthopaedic surgery because these infections often did 
not elicit a systemic inflammatory response.  
    In conclusion, two novel automated canine-specific CRP assays were developed and 
validated with satisfactory results. The tests showed high practicability for measuring 
CRP in samples from clinical research studies. Availability of these assays will facilitate 
the use of CRP as a routine diagnostic test in veterinary medicine, and can improve 
quality in research on canine inflammatory diseases.  
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1 Introduction 
Canine C-reactive protein (CRP) is a well-established inflammatory marker in 
dogs. Healthy dogs have low circulating concentrations of CRP, whereas there 
is a rapid and marked increase in CRP concentration during systemic 
inflammatory disease. The magnitude of increase in CRP concentration reflects 
the degree of systemic inflammation, and successful treatment leads to a rapid 
decline in CRP concentration. These properties make CRP a valuable marker 
both for diagnosing and monitoring systemic inflammatory diseases in dogs 
(Eckersall & Bell, 2010; Cerón et al., 2005; Kjelgaard-Hansen, 2004).  
The use of CRP as a diagnostic test in canine medicine has however been 
hampered by the lack of automated, canine-specific CRP assays. Instead, 
measurements of canine CRP in routine practice have commonly been done with 
immunological assays developed for measuring CRP in human beings. Because 
human and canine CRP are not identical, the human-based assays did not 
perform optimally when measuring canine CRP (Kjelgaard-Hansen, 2010; Caspi 
et al., 1984). Moreover in the research setting, there was a demand for better 
CRP tests. For example, automated canine-specific assays that could measure 
very low CRP concentrations with high precision were needed.  
The need for improved assays for measuring canine CRP was the main reason 
for initiating the current project. Availability of such assays should enable a 
more widespread use of CRP as a marker of systemic inflammation in dogs, both 
in clinical practice and in research.   
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2 Inflammation  
Inflammation is a non-specific response to noxious stimuli, which can remove 
harmful agents and initiate repair of damaged tissue (Hansson, 1996). Causes of 
inflammation include infection, aseptic tissue injury, neoplastic growth, and 
immunological disorders (Heinrich et al., 1990). In early descriptions of 
inflammation, focus was on the local inflammatory signs redness (rubor), 
swelling (tumour), heat (calor), pain (dolor), and loss of function (functio laesa) 
(Scott et al., 2004; Benaroyo, 1994; Rocha e Silva, 1978). With the availability 
of more advanced technologies to study biological processes, the concept of 
inflammation broadened. Using microscopy it was possible to identify 
infiltration of leukocytes in damaged tissue, and today direct measurements of 
pro-inflammatory mediators such as cytokines can be performed (Scott et al., 
2004). If inflammation is defined as a condition where the concentrations of pro-
inflammatory mediators are increased, i.e. using a biochemical definition of 
inflammation, low-grade systemic inflammation can be found also in subjects 
without clinical signs of inflammation (Pedersen & Febbraio, 2008; Scott et al., 
2004). 
Cytokines play a major role in the induction and regulation of inflammation. 
They constitute a heterogeneous group of proteins and polypeptides, regulating 
intercellular communication. After an inflammatory stimulus, cytokines such as 
interleukin (IL)-1, IL-6 and tumor necrosis factor (TNF)α are produced by 
various cell types including macrophages, lymphocytes, endothelial cells and 
fibroblasts (Thomson & Lotze, 2003). The cytokines operate in a complex 
signalling network, where combinations of cytokines can have additive, 
inhibitory and synergistic effects (Mackiewicz et al., 1991). Locally, the 
cytokines are involved in chemotaxis, angiogenesis and apoptosis  (Epstein & 
Luster, 1998; Mangan & Wahl, 1991). Cytokines also induce systemic effects, 
because they act on organs distant from the local inflammatory site activating 
receptors on different target cells (Gruys et al., 2005). This leads to a large 
number of cellular, metabolic and hormonal changes (Bode et al., 2012; Epstein 
et al., 1999; Hansson, 1996; Heinrich et al., 1990) (Figure 1).  
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Figure 1. Behavioural changes and cellular, metabolic, and hormonal effects in systemic 
inflammation. Hansson (1996), with permission.  
 
In the clinical setting it is often appropriate to make a distinction between 
local and systemic inflammation (Figure 2). The reason for needing to separate 
local from systemic inflammation is that diagnostic procedures and patient 
management differ in the two conditions. In local inflammation, diagnosis is 
based on direct examination of the affected area for example by palpating a 
swollen, painful structure, or by evaluating cell numbers in samples from the 
tissue (Bauer et al., 2012). This is in contrast to systemic inflammation, which 
can be diagnosed based on haematological and biochemistry changes in 
peripheral blood samples (Figure 1). Whereas local inflammation may cause 
discomfort and pain, the general condition of the animal is typically not affected. 
Animals with systemic inflammation, on the other hand, often show clinical 
signs such as depression and anorexia. Systemic inflammation may develop into 
a life-threatening condition (Gebhardt et al., 2009), and these patients thus need 
to be more closely monitored compared with dogs with local inflammation only. 
There is no sharp line between local and systemic inflammation, but rather a 
continuum. Mild local inflammation does not cause significant systemic 
inflammation (Bauer et al., 2012), but in cases of more severe local 
inflammation a systemic inflammatory response is expected  (Yamashita et al., 
1994). 
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Figure 2. Clinical changes occurring in local and systemic inflammation. Modified from Hansson 
(1996), with permission. 
To summarize, inflammation is a broad concept which can be defined by 
clinical, cellular and biochemical changes (Scott et al., 2004). In a clinical setting 
it is helpful to distinguish between local and systemic inflammation, as this may 
affect the choice of diagnostic tests and treatments.  
 
2.1 The acute phase proteins 
In systemic inflammation, the protein synthesis in the liver changes as a 
consequence of increased concentrations of pro-inflammatory cytokines (Figure 
1). Proteins whose circulating concentrations change by more than 25% during 
inflammation are called acute phase proteins (Eckersall & Bell, 2010). They are 
classified as positive or negative acute phase proteins, depending on whether 
their concentration increases or decreases during inflammation. Positive acute 
phase proteins are further classified by the magnitude of their increase, with 
moderate acute phase proteins showing a 2- to 10-fold increase, and major acute 
phase proteins a 10- to 100-fold increase, during systemic inflammation (Table 
1) (Cerón et al., 2005). In healthy animals, the concentrations of major acute 
phase proteins are generally lower than the concentrations of moderate acute 
phase proteins (Cerón et al., 2005; Murata et al., 2004). Thus, the difference in 
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protein concentration between healthy and diseased dogs is more pronounced 
for the major acute phase proteins compared with the moderate ones. 
Table 1. Examples of canine acute phase proteins and their functions. Data are derived from review 
articles, where references to original studies are available (Cerón et al., 2005; Murata et al., 2004). 
APP; acute phase protein 
Name Classification Function(s) 
Fibrinogen Moderate, positive APP Fibrin formation, tissue repair 
 
Haptoglobin Moderate, positive APP Involved in host defence, binding 
of free haemoglobin. 
 
Alpha 1-acid glycoprotein Moderate, positive APP Anti-inflammatory and 
immunomodulatory effects 
 
Ceruloplasmin Moderate, positive APP Protection against oxidant 
compounds, transport of copper 
 
C-reactive protein Major, positive APP Opsonisation, induction of 
cytokine production 
 
Serum Amyloid A Major, positive APP Lipid metabolism and transport, 
regulation of inflammation 
 
Albumin Negative APP Maintain colloid osmotic 
pressure, transport protein 
 
Transferrin Negative APP Iron transport 
 
For diagnostic purposes, major positive acute phase proteins are the most 
relevant to measure because they efficiently discriminate between dogs with and 
without systemic inflammation  (Christensen et al., 2014). Their concentrations 
start to increase already hours after initiation of inflammation and decline rapidly 
when the inflammatory stimulus is removed, in contrast to the moderate acute 
phase proteins whose concentrations change more slowly (Cerón et al., 2005; 
Murata et al., 2004). When comparing the two major acute phase proteins Serum 
Amyloid A (SAA) and CRP as diagnostic tests in dogs, SAA seems to be the 
more sensitive inflammatory marker of the two (Christensen et al., 2014). 
However, SAA is a protein that is difficult to purify (Christensen et al., 2013) 
and automated canine-specific SAA assays have not been commercially 
available. Thus, CRP has emerged as the most widely used major acute phase 
protein in canine medicine.   
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3 Canine C-reactive protein 
3.1 General characteristics of C-reactive protein 
Canine CRP has a molecular weight of approximately 100 kDa and consists of 
five non-covalently associated subunits arranged symmetrically around a central 
pore (Jasensky et al., 2014; Caspi et al., 1984) (Figure 3). Two of the subunits 
of canine CRP are glycosylated (Caspi et al., 1984), in contrast to human CRP 
that is not a glycoprotein (Das et al., 2003). Protein sequencing of native canine 
CRP has been performed, showing 60% homology with human CRP (Jasensky 
et al., 2014).  
 
 
Figure 3. Molecular structure of human CRP. Reprinted with permission (http://www.ebi.ac.uk). 
 
The liver is the main site of CRP production (Kushner & Feldmann, 1978; 
Hurlimann et al., 1966). The transcription of the CRP gene in the hepatocytes is 
upregulated by IL-6, and is enhanced by the presence of IL-1 (Kushner et al., 
1995; Castell et al., 1989; Ganapathi et al., 1988). There is no storage pool of 
CRP (Kushner & Feldmann, 1978), and consequently increased CRP 
concentration during inflammation can be explained by de novo synthesis. 
Extrahepatic CRP production in low concentrations has been reported, but is not 
considered to significantly affect circulating CRP concentrations (Casals et al., 
1998; Kuta & Baum, 1986).  
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In humans, the half-life of radiolabelled CRP was reported to be 19 hours 
both in healthy subjects and in patients with systemic inflammatory disease 
(Vigushin et al., 1993). The half-life of canine CRP is not known. 
Various functions of CRP have been described. The protein binds to 
pathogens and ligands on damaged cells and function as an opsonin, and thus 
plays part in the early defence of the innate immune system (Hart et al., 2004; 
Du Clos, 2000; Volanakis & Wirtz, 1979). Furthermore, CRP activates the 
complement system (Mold et al., 1999), induces cytokine production (Ballou & 
Lozanski, 1992) and play a role as a regulatory protein (Du Clos, 2003; Gershov 
et al., 2000). The fact that CRP has been well-preserved through evolution and 
is present in many different organisms, also in primitive ones (Robey & Liu, 
1981), indicates that it is a protein of importance for the immune system.  
  
3.2 Physiological factors affecting C-reactive protein 
concentrations  
In order to successfully apply CRP as a diagnostic test, knowledge about 
physiological factors affecting CRP concentrations is required. Baseline CRP 
concentrations are generally low, < 10 mg/l (Kjelgaard-Hansen et al., 2003b; 
Kuribayashi et al., 2003; Yamamoto et al., 1994b; Caspi et al., 1987), and were 
reported not to be affected by diurnal variation, sex or age (Kuribayashi et al., 
2003; Otabe et al., 1998). The effect of breed on CRP concentration has been 
scarcely studied. There was no difference in CRP concentrations when 
comparing Greyhounds with other breeds (Lucas et al., 2015; Couto et al., 2009) 
whereas other studies indicate that minor breed differences in CRP concentration 
may exist (Fergestad et al., 2016; Wong et al., 2011). In human beings, there is 
a CRP gene polymorphism which can explain differences in CRP concentration 
in healthy people of different ethnicities (Zhu et al., 2013). It remains to be 
investigated whether this is the case also in dogs.   
C-reactive protein concentrations in female dogs were not affected by oestrus 
cycle stage (Ulutas et al., 2009). In contrast, pregnancy did affect CRP 
concentrations with maximal levels observed day 30-45 after ovulation 
(Kuribayashi et al., 2003; Eckersall et al., 1993). The mean CRP concentration 
in pregnant beagles during this period was 77.5 mg/l, compared to < 10 mg/l in 
non-pregnant healthy dogs (Kuribayashi et al., 2003). It has been proposed that 
the increase in CRP concentration during pregnancy is associated with 
implantation of the foetuses (Eckersall et al., 1993), or that CRP is influenced 
by altered levels of endocrine hormones (Kuribayashi et al., 2003). However, no 
clear cause for the increased CRP concentrations found during pregnancy has 
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been established. There are other studies where no increase in CRP concentration 
was observed in pregnant dogs (Ulutas et al., 2009; Concannon et al., 1996), and 
the reason for this discrepancy is not known. The possibility that analytical 
problems occurred in some of the studies cannot be excluded because it is 
difficult to find a biological explanation for this marked variation.   
Knowledge about effect from exercise on CRP concentration is important for 
clinicians using CRP as a diagnostic test, because physical activity is highly 
variable in dogs admitted to veterinary care. In sled dogs participating in long-
distance endurance exercise, an increased CRP concentration was observed after 
racing compared to before the race. Mean CRP concentrations after racing were 
between 39 mg/l and 263 mg/l in different studies, which corresponded to a 
clinically significant increase (Fergestad et al., 2016; Spoo et al., 2015; 
Yazwinski et al., 2013; Kenyon et al., 2011; Wakshlag et al., 2010b). The 
increased CRP concentrations could be explained by strenuous exercise eliciting 
an inflammatory response in various organs or by release of IL-6 from skeletal 
muscles during exercise, as has been described in humans (Trayhurn et al., 2011; 
Pedersen & Febbraio, 2008). After exercise of short duration, only mild and 
clinically insignificant increases of CRP concentrations were observed (Lucas et 
al., 2015; Krogh et al., 2014; Wakshlag et al., 2010a). It can be concluded that 
the effect from exercise on CRP concentration depends on the duration and 
magnitude of the physical effort. Therefore, it is only for dogs that have been 
subjected to long-term strenuous exercise that the clinician needs to take 
physical activity into consideration when interpreting CRP results.   
Physiological stress induced by road transportation did not lead to a clinically 
significant increase in CRP concentration (Fazio et al., 2015). The lack of effect 
from the stress hormone cortisol on baseline CRP concentrations was also 
illustrated by the finding that dogs with hyperadrenocorticism did not have 
altered CRP concentrations compared to healthy dogs (Caldin et al., 2009).  
In conclusion, little variation is expected to occur in CRP concentrations due 
to physiological variations, except during pregnancy and after strenuous 
exercise. Therefore, an increased CRP concentration in a dog is highly specific 
for systemic inflammation. 
 
3.3 C-reactive protein as a marker of systemic inflammation  
Measurement of CRP is valuable in a clinical setting to diagnose systemic 
inflammation in dogs. Increased CRP concentrations have been reported in a 
large number of conditions, including bacterial, viral and parasitic infection 
(Méndez et al., 2015; Fransson et al., 2004; Yamamoto et al., 1993), immune-
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mediated disease (Griebsch et al., 2009; Ohno et al., 2006), neoplasia (Tecles et 
al., 2005), sterile inflammation (Yuki et al., 2015; Bayramli & Ulutas, 2008; 
Otabe et al., 2000; Yamashita et al., 1994), and surgical trauma (Christensen et 
al., 2015). In studies investigating large numbers of dogs with and without 
systemic inflammatory diseases, it was shown that CRP concentration efficiently 
discriminated between the two groups (Christensen et al., 2014; Nakamura et 
al., 2008).  
The kinetics of CRP have been studied both in natural and experimentally 
induced inflammation. Generally, an increase in blood CRP concentration 
occurs within 4-6 hours after an inflammatory stimulus, reaching the maximum 
concentration after about 24-48 hours (Kuribayashi et al., 2015; Kjelgaard-
Hansen et al., 2013; Kum et al., 2013; Ishida et al., 2011; Nevill et al., 2010; 
Yamashita et al., 1994; Yamamoto et al., 1992; Ganrot, 1973). The magnitude 
of increase in CRP concentration reflects the degree of tissue trauma (Kjelgaard-
Hansen et al., 2013; Otabe et al., 2000; Yamamoto et al., 1993), and CRP 
concentrations decline with successful treatment of inflammatory diseases 
(Méndez et al., 2015; Yuki et al., 2015; Seo Kw Fau - Lee et al., 2012; Merlo et 
al., 2007; Nielsen et al., 2007; Ohno et al., 2006; Ndung'u et al., 1991). It can 
thus be concluded that CRP concentration not only provides information on 
whether systemic inflammation is present or not, but it can also be used to 
quantify the degree of inflammation.  
It has been hypothesised that measuring CRP concentration would be of 
prognostic value, which is plausible bearing in mind that CRP is a quantitative 
inflammatory marker. The idea is that severe systemic inflammation should be 
associated both with a high CRP concentration, and with a poor prognosis. 
However, a single CRP measurement was not effective for judging prognosis in 
dogs with immune-mediated haemolytic anaemia (Griebsch et al., 2009; 
Mitchell et al., 2009), sepsis (Torrente et al., 2015; Gebhardt et al., 2009), 
pancreatitis (Yuki et al., 2015; Mansfield et al., 2008), babesiosis (Koster et al., 
2009), acute abdomen syndrome (Galezowski et al., 2010), or in critically ill 
dogs (Chan et al., 2009). One explanation for this could be that CRP 
concentration only provides information about a limited part of the complicated 
inflammatory cascade. The cytokines involved in inflammation have both pro- 
and anti-inflammatory properties (Blackwell & Christman, 1996), and CRP 
concentration reflects the activity of the pro-inflammatory ones. It is possible 
that knowledge about the balance between pro- and anti-inflammatory mediators 
would enable more effective prognostication, but this information is currently 
not available in routine clinical practice. Another reason for why a single CRP 
value is not prognostic in inflammatory disease could be that the location of the 
inflammation is of importance. For example, inflammation in the central nervous 
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system may be devastating, even if it does not elicit a marked systemic 
inflammatory response (Vestergaard et al., 2013). On the other hand, a disease 
such as pyometra which causes severe systemic inflammation often have 
favourable prognosis, because effective treatment is available. Finally, the time 
point of sampling is important, considering that there is a delay of about 24 hours 
from an inflammatory stimulus until the maximal CRP concentration is 
observed. Therefore, if a dog is sampled early in the disease process, the CRP 
concentration does not yet correctly reflect the degree of inflammation.  
Although a single measurement of CRP is not of prognostic value, it has been 
shown that decreasing CRP concentration over time in a patient is a favourable 
sign (Gebhardt et al., 2009; Ohno et al., 2006). Marked changes in CRP 
concentration can occur over a short period of time, with a decrease in CRP 
concentration of ~50% in 24 hours (unpublished data) to 48 hours (Gebhardt et 
al., 2009; Dabrowski et al., 2007; Ohno et al., 2006). This justifies the use of 
iterated measurements of CRP in dogs with systemic inflammatory diseases for 
monitoring. Considering how rapidly CRP concentrations can change over time, 
sampling with no more than 24 hours interval is probably relevant in selected 
cases.    
A frequently asked question in veterinary practice is whether systemic 
inflammation in a dog is caused by bacterial infection or not, which is important 
because the answer often affects the choice of treatment. Because CRP is an 
unspecific marker of systemic inflammation, it cannot be used as a standalone 
test for diagnosing bacterial infection (Gebhardt et al., 2009; Bathen-Noethen et 
al., 2008). However, in people it has been shown that CRP measurements can 
be useful for indicating presence of bacterial infection when used in a specific, 
well-defined context (Cals et al., 2010; Muller et al., 2008). In dogs too, there 
are situations where this may be applicable, for example in respiratory disease 
(Viitanen et al., 2014). It must be emphasized though that it is only by 
interpreting CRP results together with anamnestic history and clinical findings, 
that the test has the potential to provide such information.  
Because CRP is produced by hepatocytes, (Hurlimann et al., 1966), liver 
dysfunction could theoretically affect CRP concentrations. This has been 
investigated in human beings, where it was shown that CRP production was 
maintained during systemic inflammation despite advanced liver dysfunction 
(Pieri et al., 2014; Park et al., 2005). There are no similar studies in dogs, but 
increased CRP concentrations have been reported in dogs with chronic hepatitis 
and congenital portosystemic shunts indicating that dogs affected by these 
diseases are able to produce CRP (Gow et al., 2012; Nakamura et al., 2008). In 
people it was described that the more severe the underlying liver dysfunction, 
the lower the increase in CRP concentration was in the case of concurrent 
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bacterial infection (Pieri et al., 2014). This suggests that the CRP response may 
be blunted in humans with hepatic dysfunction, and it remains to be investigated 
whether this is the case also in dogs. A blunted CRP response after an 
inflammatory stimulus has previously been reported in canine patients with 
hyperadrenocorticism (Caldin et al., 2009), and in dogs of age ≤ 3 months  
(Hayashi et al., 2001). Thus, clinicians should be aware of the risk of 
underestimating the magnitude of systemic inflammation when interpreting CRP 
results in the above-mentioned patient groups.   
Besides being a marker of systemic inflammation in a clinical setting, CRP 
concentrations have also been measured in research investigating conditions 
suspected to be associated with low-grade inflammation, such as obesity 
(Eirmann et al., 2009; Veiga et al., 2008; Yamka et al., 2006). The purpose of 
performing this type of studies is to learn more about the pathophysiology behind 
these conditions, rather than to find new clinical applications for CRP. Currently, 
there are no indications that exact determinations of CRP at low concentrations 
are useful in a clinical setting, with the possible exception of monitoring 
treatment response in dogs with inflammatory bowel disease (Jergens et al., 
2010; Jergens et al., 2003). Potentially, situations will be identified in the future 
where measurement of CRP in the low range is beneficial, for example for 
detecting relapse in dogs under treatment for conditions associated with mild 
systemic inflammation.  
In conclusion, measurement of CRP is valuable for diagnosing and 
monitoring systemic inflammation in dogs. C-reactive protein is an unspecific 
inflammatory marker, and cannot by itself be used for determining the cause of 
inflammation.    
 
3.3.1 Effect of pharmaceuticals on C-reactive protein concentration 
If treatment with pharmaceuticals directly affects the concentration of an 
inflammatory marker, it may diminish the marker’s diagnostic value. This is 
apparent when using the white blood cell count for diagnosing systemic 
inflammation, because a stress leukogram caused by glucocorticoid treatment 
may be identical to the leukogram present in chronic inflammatory disease 
(Jasper & Jain, 1965). This is in contrast to CRP, whose concentrations were not 
affected by glucocorticoid treatment neither in healthy dogs, nor in dogs with 
systemic inflammation (Martinez-Subiela et al., 2004; Yamamoto et al., 1994a). 
The lack of direct effect from glucocorticoids on CRP concentration makes CRP 
a suitable marker for monitoring inflammation in dogs under prednisolone 
treatment for immune-mediated disease (Lowrie et al., 2009; Kjelgaard-Hansen 
et al., 2006; Ohno et al., 2006). In such a patient, a change in CRP concentration 
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directly mirrors the inflammatory activity, without being biased by the drug 
itself.  
No effect from NSAID treatment on CRP concentration was reported in dogs 
undergoing surgery (Kum et al., 2013) or in dogs with experimentally induced 
synovitis (Borer et al., 2003). Treatment with low-dose ketamine was described 
to decrease postoperative CRP concentrations in dogs undergoing 
ovariohysterectomy due to pyometra, and it was hypothesized that ketamine had 
an anti-inflammatory effect in these patients (Liao et al., 2014). Considering that 
ketamine is not a common treatment like glucocorticoids and NSAIDs, and that 
it is not for long-term use, this finding is probably of limited importance for 
veterinarians using CRP in a clinical setting. 
To summarize, CRP concentration is not affected by treatment with 
glucocorticoids or NSAIDs, which is highly advantageous for a clinical marker 
of systemic inflammation.   
 
3.4 Measurement of C-reactive protein 
Canine CRP was first measured in 1972, using a  capillary immune-reaction 
(Riley & Zontine, 1972). Since, several canine-specific CRP immunoassays 
have been developed including but not limited to ELISAs (Kjelgaard-Hansen et 
al., 2003b; Yamamoto et al., 1992; Eckersall et al., 1989), electroimmunoassays 
(Caspi et al., 1984), time resolved immunofluorometric assays (Parra et al., 
2006), laser nephelometric immunoassays (Onishi et al., 2000), and 
immunoturbidimetric assays (Eckersall et al., 1991).  
In 2003, a canine-specific ELISA test was validated and later became widely 
used in research on canine inflammatory diseases for quantification of CRP 
concentrations both in the high and the low range  (Ljungvall et al., 2010; 
Fransson et al., 2004; Kjelgaard-Hansen et al., 2003b). However, the ELISA 
method is time consuming, lacks random-accessibility during analytical runs, 
and has relatively high imprecision. Automated CRP tests were thus requested 
by veterinary laboratories, and a few such assays were developed including 
canine-specific immunoturbidimetric and nephelometric methods (Onishi et al., 
2000; Eckersall et al., 1991). However, these tests never reached a broad 
commercial market. Instead, an assay developed for measuring human CRP was 
validated for use in dogs (Klenner et al., 2010; Kjelgaard-Hansen et al., 2003a), 
and became a routine test at several veterinary diagnostic laboratories 
(Kjelgaard-Hansen, 2010). The heterologous determination of canine CRP with 
this immunoturbidimetric assay was possible because of sufficient cross-
reactivity towards canine CRP by the polyclonal anti-human CRP antibodies of 
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the test (Kjelgaard-Hansen et al., 2003a). However, poor cross-reactivty 
between human and canine CRP had previously been reported (Yamamoto et 
al., 1992; Caspi et al., 1984), and stable performance of the human-based 
immunoturbidimeteric assay could not be guaranteed across reagent batches. 
Therefore, batch level validation studies were required, and it was recommended 
to use purified canine CRP for calibration (Kjelgaard-Hansen, 2010; Eckersall, 
1995). Because of this, the human-based immunoturbidimetric test worked 
satisfactory only in laboratories where the above-mentioned challenges could be 
properly addressed.  
In conclusion, although canine CRP had been measured by several different 
methods throughout the years, there was a need for assays that were both 
automated and canine-specific, enabling precise CRP measurements and stable 
performance over time.   
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4 Validation of analytical performance 
4.1 Method validation experiments 
Method validation studies are performed to confirm that the requirements of a 
specified intended use for a test are fulfilled (Taverniers et al., 2004a). For an 
assay that will be used in a clinical setting, this corresponds to reassuring that 
analytical error will not negatively impact patient management. Guidelines on 
recommended protocols for method validation studies are available from 
regulatory agencies such as the Clinical and Laboratory Standards Institute 
(CLSI), and validation study protocols can be found in the literature 
(Magnusson, 2014; Westgard, 2008; Taverniers et al., 2004b).  
Various performance criteria of a method are evaluated to judge whether or 
not the assay has acceptable performance. One such criterion is precision, which 
is defined as the “closeness of agreement between independent measurements 
obtained under stipulated conditions” (CLSI, 2004). Precision is a measure of 
random error. If precision is low, there is large variation in the results from 
repeated analysis of the same, single sample (Figure 4). Precision is usually 
determined in two forms. Analysing the same sample repeatedly within one run 
determines the intra-assay variation, and analysing the sample repeatedly over 
an extended period of time determines the inter-assay variation. The 
circumstances under which precision studies take place affects the result, with 
the highest precision being expected when experiments are carried out under 
controlled conditions over a short period of time. For a laboratory analysing 
routine patient samples, it is important to determine long-term precision 
covering multiple calibrator and reagent batches, operators and environmental 
conditions (White & Farrance, 2004).  
Laboratory test reports released to practitioners generally do not contain 
information about analytical precision. It has been suggested that exact values 
reported from the laboratory should be accompanied by a range in which the true 
value is likely to lie with a stated probability (White, 2008). For example, a 
reported value of 50 units could have 95% probability to be somewhere between 
40 and 60 units if using an assay with low precision, or between 49 and 51 units 
if using a highly precise assay. This information is important when the test result 
is interpreted. However, for practical reasons and by habit, information about 
precision is not included in laboratory test reports. It is the responsibility of the 
laboratory performing the test not to release results that are afflicted by random 
error of a magnitude that may negatively impact patient management.  
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Figure 4. Graphical illustration of random and systematic error. A sample with a known value is 
repeatedly analysed. The random error represents the variation in the observed results. The 
systematic error represents the distance between the mean observed value and the true value.  
 
Bias is a measure of systematic error, defined as the difference between the 
measured value and the true value of a measurand (Taverniers et al., 2004a) 
(Figure 4). Bias is of importance if results from different analytical methods or 
laboratories are to be compared to each other or if reference intervals and clinical 
decision limits are transferred between different settings. If, for example, a new 
assay systematically measures analyte concentrations that are twice as high as a 
previously used method, misinterpretations due to bias will occur if the same 
clinical decision limits are used for both methods. However, problems caused by 
bias can be overcome by establishing reference intervals and clinical decision 
limits for each specific test, and by avoiding direct comparison of test results 
obtained with different assays. This is commonly performed in veterinary 
laboratories where bias is often unknown because reference methods, or 
reference materials with known analyte concentrations, are not available. In 
some situations, such as when canine CRP is measured directly with assays 
developed for measuring human CRP, a significant systematic error is expected 
to occur (Kjelgaard-Hansen, 2010; Klenner et al., 2010). However, if necessary 
actions are undertaken to handle the problem, such methods may still be useful 
in veterinary laboratories.  
In the validation of a CRP assay, it is also crucial to evaluate whether a  
prozone effect is present. The prozone effect, also called the high-dose hook 
effect, is a phenomenon that occurs in immunological assays when there is 
antigen excess in a sample, preventing successful formation of appropriate 
antigen-antibody complexes (Jacobs et al., 2015). There is an increased risk of 
prozone effect if the measured analyte is present in a wide concentration range 
(Jacobs et al., 2015), which is true for major positive acute phase proteins such 
as canine CRP. A possible consequence of prozone effect is that false low results 
are reported for samples that actually have extremely high concentrations of the 
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analyte, which may cause severe misinterpretation directly affecting patient care 
(Jacobs et al., 2015). Therefore, absence of relevant prozone effect must be 
confirmed prior to introducing a new analytical method for measuring CRP.   
In conclusion, the purpose of a method validation study is to reassure that an 
assay has acceptable performance before it is taken into use. The number and 
type of experiments performed in a method validation study depends on the 
intended use of the assay. Experiments considered relevant to perform in the 
validation of canine CRP assays are described in detail in Paper I and II of this 
thesis.   
 
4.2 Setting analytical quality specifications and analysis of data 
As previously stated, the purpose of a method validation is to confirm that an 
assay has acceptable performance. The next question then is how to determine 
what constitutes an acceptable performance. There are different methods 
available for setting analytical quality specifications, and the preferred one is to 
directly evaluate the effect of analytical performance on clinical outcomes 
(Sandberg et al., 2015; Kenny et al., 1999). Because such studies are 
complicated and resource-demanding to perform, they are often lacking in 
veterinary medicine. Other approaches for determining analytical quality goals 
include using data on biological variation, or relying on expert recommendations 
(Kenny et al., 1999). What is considered to be acceptable performance varies 
substantially between different analytes, and may also vary for the same analyte 
depending on its concentration or the situation where it is applied. Thus, 
acceptable performance must be judged in a context where the intended use of 
the assay is specified.  
In the current work, biological variation was used to set quality requirements. 
Although this is not the superior method for determining quality goals, it is still 
considered as a relevant measure that has the advantage of being objective, in 
contrast to several of the other proposed methods (Kenny et al., 1999). 
Biological variation is defined as the random fluctuation of an analyte around a 
homeostatic setting point. It is composed of CVI, reflecting changes occurring 
within the same individual over time, and CVG, representing the difference 
between individuals (Fraser, 2001). When data on biological variation are used 
to set analytical quality specification, the attempt is to minimize the ratio of 
“analytical noise” to the biological signal used in diagnosis (Sandberg et al., 
2015). The analytical desirable performance goal, CVA, can be calculated 
according to the formula 0.5 x CVI . This should be interpreted as follows: the 
analytical variability added to the already existing intra-individual variability 
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will be equivalent to 11.8% if CVA is 0.5 x CVI. The formula for calculating 
desirable bias is 0.25(CVI2 + CVG2)0.5 (Fraser, 2001). Knowledge about desirable 
bias is useful for example when a reference interval obtained with a reference 
test is transferred to a new method. Normally, reference intervals include 95% 
of the healthy population. If the bias of the new assay is equal to 0.25(CVI2 + 
CVG2)0.5 it means that 5.8% instead of 5% of the normal population will fall 
outside the reference interval, which is considered to be acceptable.   
Data on desirable bias and imprecision can be combined to create a single 
measurement representing the total error allowed for a test (TEa) (Harr et al., 
2013; Westgard, 2008). In method validation studies, the total error (TE) can be 
determined by adding a test’s imprecision and bias as determined in the 
validation experiments (Westgard, 2008). The calculated TE is then compared 
to the TEa, and if TE < TEa it can be concluded that the assay has acceptable 
performance.  
The concept of TE has met criticism (Oosterhuis & Theodorsson, 2015; 
White, 2008), and it can be questioned whether it is relevant to add two such 
different entities as imprecision and bias. One argument is that either bias is 
known, and then it should be corrected for, or bias is unknown and then it cannot 
be used for calculating TE. Instead of using TE, it has been proposed that focus 
should be on measurement uncertainty. This is defined as “a parameter, 
associated with the result of a measurement, that characterizes the dispersion of 
the values that could reasonably be attributed to the measurand” (JCGM, 2008). 
While error is a value describing the difference between an individual analytical 
result and the true value of the measurand, the uncertainty of a measurement is 
the doubt that exists about the result of any measurement (White, 2008; 
Taverniers et al., 2004a). The International Organization for Standardization 
(ISO) advocates use of measurement uncertainty (JCGM, 2008), while the TE 
approach is recommended by the American Society for Veterinary Clinical 
Pathologists (Harr et al., 2013). It has been suggested that TE and measurement 
uncertainty can be implemented simultaneously, but for different purposes, in 
the laboratory (Rozet et al., 2011).  
To summarize, at this point there is no consensus regarding how TE and 
measurement uncertainty should be handled, and the topic is currently being 
discussed within the veterinary laboratory community. 
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5 Aims of the thesis 
The overall aim of the thesis was to develop and validate new assays optimized 
for measuring canine CRP. Availability of such assays should improve the use 
of CRP as an inflammatory marker both in clinical practice and in research. An 
additional aim was to conduct clinical studies to evaluate CRP as a quantitative 
marker of systemic inflammation in dogs, and to examine the diagnostic value 
of measuring CRP in specific settings.  
 
Specific aims were to: 
 
 Validate two immunoturbidimetric automated canine-specific CRP 
assays for measuring serum CRP in the whole concentration range 
expected to occur in dogs.  
  
 Evaluate CRP as a quantitative marker of systemic inflammation.   
o Investigate whether CRP concentration was correlated to 
oedema, a clinical sign of local inflammation, in dogs 
envenomed by Vipera berus. It was hypothesised that the more 
severe the local inflammation, the more pronounced the 
systemic inflammation and increase in CRP concentration 
would be.  
o Measure CRP concentration in dogs with pyometra 
undergoing ovariohysterectomy, to evaluate how surgical 
treatment affected degree of systemic inflammation in these 
patients.   
 
 Evaluate the diagnostic value of measuring CRP concentration. 
o Investigate the usefulness of CRP for discriminating between 
dogs with suppurative arthritis and osteoarthritis. 
o Investigate the usefulness of CRP for diagnosing post-
operative infections after orthopaedic surgery. 
 
 Investigate whether inflammation, defined as an increased CRP 
concentration, was associated with severity of canine myxomatous 
mitral valve disease in order to increase the knowledge about the 
pathophysiology of this disease.  
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6 Materials and methods 
This section summarizes the methods used in Paper I-IV, and describes 
additional projects not included in these papers. 
In the clinical studies, client-owned dogs were enrolled prospectively with 
written consent given by the owner prior to participation. The studies were 
approved by the Local Ethical Committee on Animal Experiments, Uppsala. 
Blood samples were collected from the jugular or cephalic vein, and sera for 
CRP analysis were stored at -20°C for a maximum of 5 months, or at -80°C for 
a maximum of 6.5 years, prior to analysis.  
 
6.1 Method validation studies (Paper I and II) 
A reagent containing polyclonal chicken anti-canine CRP antibodies, conjugated 
to latex, was used in an immunoturbidimetric, automated canine-specific CRP 
assay (Gentian AS, Moss, Norway). Analyses were performed on a fully 
automated, open-system clinical chemistry/immunoassay analyser (Abbott 
Architect c4000, Abbott Park, IL, USA). Sample and reagent were mixed in the 
instrument, and when antibodies reacted with canine CRP agglutination 
occurred, leading to an increased turbidity that was measured 
spectrophotometrically (Figure 5).  
 
 
 
Figure 5. Principle of the latex-enhanced immunoturbidimetric assay. Anti-canine C-reactive 
protein (CRP) antibodies conjugated to latex particles in the reagent react with CRP in the sample 
(blue structures), leading to agglutination and an increased turbidity of the solution. 
36 
Two different instrument applications were used on the same chemistry 
analyser. The first application, referred to as the cCRP test, was adapted for 
measuring the high CRP concentrations expected in dogs with systemic 
inflammatory disease. The second application, referred to as the hsCRP assay, 
was adapted for measuring low CRP concentrations. The hsCRP assay was 
created by increasing the sample volume of the cCRP test ten-fold, from 2 µl to 
20 µl, while keeping the reagent volume unchanged. Canine-specific calibrator 
material provided from the manufacturer was used to create a six-point calibrator 
curve. For the hsCRP assay, calibrators were manually diluted 1:10 with saline 
prior to calibration. The reason for developing two different applications was 
that it was not technically possible to create one single assay that could measure 
CRP concentration in the whole concentration range expected to occur in dogs. 
An overview of the method validation experiments performed are displayed 
in Table 2. Analytical quality goals were set based on data of biological variation 
in healthy dogs (Kjelgaard-Hansen et al., 2003c). Data analysis was performed 
following CLSI guidelines or other recommendations (Jensen & Kjelgaard-
Hansen, 2006; Bland & Altman, 1986). 
 
 
Table 2. Experiments performed in the validation studies of the canine-specific C-reactive protein 
assay (cCRP) and the high-sensitivity canine-specific C-reactive protein assay (hsCRP).  
Evaluated parameter cCRP hsCRP 
Precision 
Consistency upon dilution 
Limit of Blank 
Limit of Detection 
Limit of Quantification 
Prozone effect 
Recovery after spiking 
Interference from haemoglobin/triglycerides 
Storage stability (room temperature and 4°C) 
Difference between methods (method 
comparison study) 
x 
x 
ND 
ND 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
ND 
x 
x = experiment performed  
ND = not determined                                                                                                                                   
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In the spike and recovery studies, as well as in the study of prozone effect, 
commercially available purified canine CRP was used (LifeDiagnostics, West 
Chester, PA, USA). A fat emulsion (Intralipid 200 g/l, Fresenius Kabi AB, 
Uppsala, Sweden) was used to test effect of lipemia, whereas a haemolytic 
solution was prepared from canine samples to test interference from haemolysis 
(CLSI, 2005). 
Two method comparison studies were performed. The cCRP assay was 
compared to a fully automated immunoturbidimetric CRP assay developed for 
measuring CRP in humans, previously validated for use in dogs (Kjelgaard-
Hansen et al., 2003a). The method was calibrated with canine CRP. The hsCRP 
assay was compared to a previously validated canine-specific ELISA 
(Kjelgaard-Hansen et al., 2003b). The reason for choosing these methods as 
comparative assays was that they were used at the Clinical Pathology 
Laboratory, University Animal Hospital, SLU, for measuring CRP in the high 
and low concentration range, respectively, when starting these studies. Data 
from the method comparison studies were evaluated using Bland-Altman plots 
(Bland & Altman, 1986) and Passing-Bablok regression analysis (Passing & 
Bablok, 1983).  
 
6.2 C-reactive protein as a quantitative marker of systemic 
inflammation  
6.2.1 C-reactive protein in dogs envenomed by Vipera berus (Paper III) 
This study was a randomized, placebo-controlled double-blind clinical study 
where the original aim was to evaluate the effect of prednisolone treatment on 
dogs envenomed by Vipera berus (V. berus) (Paper III). In this thesis, the data 
set from the study was used to investigate the correlation between oedema, 
which is a clinical sign of local inflammation, and CRP concentration. The 
hypothesis was that the more severe the local inflammation, the more 
pronounced the systemic inflammatory response would be, i.e. there would be a 
positive correlation between degree of oedema and CRP concentration. 
Inclusion criteria were a reported snake bite within the previous 24 hours 
prior to admission, and presence of clinical signs typical of envenomation by V. 
berus. Pregnant dogs and dogs with underlying disease including 
hyperadrenocortism, renal disease, diabetes mellitus and inflammatory disease 
were excluded. Although dogs treated with glucocorticoids, NSAID or 
antivenom were excluded in the original publication (Paper III),  they were 
included in this evaluation of correlation between oedema and CRP 
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concentration. Dogs were examined by the attending veterinary surgeon on 
presentation (Day 1), 24±6 h after presentation (Day 2), and at re-examination 
after 10-28 days. Blood samples were collected on the same three occasions.  
Oedema on Day 1 and 2 was assessed by measuring the circumference of the 
affected body part, i.e. the head or limb region. This measure was compared to 
the circumference measured at re-examination, when no oedema persisted, and 
the increase in circumference was expressed in percent. C-reactive protein 
concentration was measured with the cCRP assay in duplicate in one run. 
The correlation between degree of oedema and CRP concentration on Day 2 
was assessed with Spearman’s rank correlation coefficient (rs). Significance 
level was set at p < 0.05. 
 
6.2.2 C-reactive protein in dogs with pyometra undergoing ovariohysterectomy 
In this study, CRP concentration was used as a quantitative marker of systemic 
inflammation in dogs with pyometra undergoing ovariohysterectomy. Dogs with 
pyometra typically have a systemic inflammatory response with neutrophilia, 
left shift and increased concentrations of acute phase proteins (Fransson et al., 
2004). The preferred treatment for pyometra is ovariohysterectomy, a procedure 
that in itself causes systemic inflammation due to the tissue trauma caused by 
surgery (Kjelgaard-Hansen et al., 2013; Kum et al., 2013; Dabrowski et al., 
2007). It could be speculated that the degree of systemic inflammation would 
temporally increase when ovariohysterectomy is performed in a dog with 
pyometra, because of the additional inflammation caused by surgery. On the 
other hand, ovariohysterectomy is an effective treatment for pyometra, and the 
inflammation is expected to gradually dissolve when the inflammatory stimulus 
is removed. The aim of the current study was to investigate the overall effect on 
the degree of systemic inflammation in dogs with pyometra undergoing 
ovariohysterectomy. To do so, an objective, quantitative marker of systemic 
inflammation was required, and measurement of CRP was chosen as the 
preferred test.  
Dogs admitted to the University Animal Hospital, SLU, Uppsala, and 
AniCura Bagarmossen Small Animal Hospital, Stockholm, were included in the 
study. Inclusion criteria were diagnosis of pyometra, based on the finding of an 
enlarged, fluid filled uterus and pre-operative serum CRP concentration ≥  20 
mg/l in a dog with history and clinical findings suggestive of pyometra. Dogs 
with known concurrent  disease expected to cause systemic inflammation were 
excluded. An open ventral midline approach ovariohysterectomy was performed 
while dogs were under general inhalation anaesthesia. Analgesic treatment 
included NSAIDs and opiods, and some of the dogs received antibiotics as 
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decided by the veterinary surgeon in charge. Information about post-operative 
complications were retrieved from the medical records. Blood samples were 
collected immediately prior to and 24±3 hours after initiation of surgery, defined 
as start of the first skin incision. C-reactive protein concentration was measured 
with the cCRP assay in duplicate in one run. A Wilcoxon sign-ranked test was 
performed to compare pre- and post-operative CRP concentrations.    
 
6.3 C-reactive protein as a diagnostic test 
6.3.1 Measurement of C-reactive protein concentration for discriminating 
between suppurative arthritis and osteoarthritis in dogs (Paper IV) 
The study was performed in order to evaluate if CRP concentration could be 
used as a test for discriminating between dogs with suppurative arthritis and dogs 
with osteoarthritis (OA). Dogs admitted to University Animal Hospital, SLU, 
Uppsala or Evidensia Södra Djursjukhuset, Stockholm, were included if they 
had at least one painful joint as determined by a veterinarian at physical 
examination. It was further required that the dog should have arthrocentesis, 
arthroscopy or arthrotomy performed for diagnostic or therapeutic purposes. 
Exclusion criteria were pregnancy and glucocorticoid treatment within four 
weeks prior to sampling. Dogs were classified to have suppurative arthritis or 
OA based on findings from synovial fluid analysis, arthroscopy and radiographic 
examination. Measurement of CRP was first performed with the cCRP test, and 
samples with CRP concentrations < 6.8 mg/l were immediately reanalysed with 
the hsCRP assay.  
Statistical analyses included multiple logistic regression analysis with disease 
(suppurative arthritis or OA) as outcome, and CRP, sex, age, body weight, 
NSAID treatment, and presence of concurrent disease as explanatory variables. 
CRP data were transformed to the base 2-logarithmic scale (log2CRP) to 
facilitate interpretation of results: for a doubling of CRP concentration, the odds 
of having inflammatory arthritis increased by a factor corresponding to the odds 
ratio. Backward step-wise elimination of explanatory variables based on p-
values was used to reduce the model until all included variables had a p-value   
< 0.05. Explanatory variables whose inclusion changed the beta coefficient of 
log2CRP by > 20% were considered possible confounders, and were retained in 
the model. The goodness of fit was tested with the Hosmer and Lemeshow test. 
The diagnostic performance of CRP for discriminating between suppurative 
arthritis and OA was further assessed by receiver operating characteristic (ROC) 
curve analysis. C-reactive protein concentrations were also compared against a 
locally established clinical decision limit for CRP, 20 mg/l. The decision limit 
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was determined by performing ROC curve analysis of CRP data from dogs with 
and without known systemic inflammatory disease (data not shown), similarly 
to what has been previously described (Christensen et al., 2014). Correct 
classification was defined as CRP concentration ≥ 20 mg/l in a dog with 
suppurative arthritis, and CRP concentration < 20 mg/l in a dog with OA. 
 
6.3.2 C-reactive protein concentration as a test for diagnosing post-operative 
infections after orthopaedic surgery 
The objective of the study was to investigate whether measurement of CRP 
concentration was useful for diagnosing late post-operative bacterial infections 
in dogs after orthopaedic surgery. It was hypothesised that dogs with post-
operative infections would have more pronounced systemic inflammations, and 
therefore higher CRP concentrations, compared to dogs with non-infectious 
complications such as implant loosening. 
Inclusion criteria were that the dog had clinical signs compatible with post-
operative infection including swelling, pain, and/or drainage at the surgical site, 
and/or joint effusion in a previously operated joint. Furthermore, the dog should 
have had orthopaedic surgery performed at least 20 days earlier, but no longer 
than 365 days earlier. Exclusion criteria were other known inflammatory 
disease, pregnancy and treatment with antibiotics. Blood samples were collected 
prior to performing any other diagnostic or therapeutic interventions.  
Diagnostic procedures included bacterial culture of samples collected from 
the suspected infected area, cytology, and radiographic examination. Bacterial 
culturing was performed at the Section of Bacteriology, National Veterinary 
Institute, Uppsala, Sweden. All dogs had at least two of the above-mentioned 
diagnostic procedures performed. Dogs were classified as infected if there was 
significant growth of bacteria at bacterial culture, and/or if neutrophils and 
intracellular bacteria were found at cytological examination. Dogs that had no 
signs of infection with any of the diagnostic tests performed were classified as 
not infected. Dogs with inconclusive test results were excluded.  
A group of control dogs that showed no signs of complications after 
orthopaedic surgery were included. Blood samples were collected from the 
control dogs during the same time period after surgery as for the cases, after 
performing a physical examination where no clinical signs compatible with post-
operative infection were detected.  
Information about the dogs, history, clinical findings, surgical procedures, 
and treatments was obtained from medical records. C-reactive protein 
concentration was measured with the cCRP assay in duplicate in one run, and 
concentrations in the different groups were compared using the Mann-Whitney 
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U test. Significance level was set at p < 0.05. C-reactive protein concentrations 
were further compared against the locally established clinical decision limit for 
CRP, 20 mg/l. Correct classification was defined as CRP concentration ≥ 20 
mg/l in a dog with infection and < 20 mg/l in a dog without infection. 
 
6.4 Application of the high-sensitivity C-reactive protein assay 
on samples from dogs with myxomatous mitral valve 
disease  
The hsCRP assay was applied on samples from dogs with myxomatous mitral 
valve disease (MMVD), with the aim to evaluate whether CRP concentrations 
reflected well the severity of MMVD. This was considered interesting to study, 
as a link between systemic inflammation and cardiovascular disease has been 
suggested to exist in dogs (Cunningham et al., 2012). Based on this, it was 
hypothesised that CRP concentrations would be positively correlated to severity 
of MMVD. 
The included dogs had been enrolled in previous investigations in Sweden and 
Denmark (Reimann et al., 2014a; Reimann et al., 2014b; Ljungvall et al., 2011a; 
Ljungvall et al., 2011b; Ljungvall et al., 2010). The dogs underwent physical 
examinations including blood pressure measurements and echocardiography, 
and a full clinical history was obtained from each owner. Dogs with history or 
signs of cardiovascular disease other than MMVD, or other significant disease, 
were excluded. MMVD severity was determined on the bases of the American 
College of Veterinary Internal Medicine (ACVIM) consensus statement (Atkins 
et al., 2009). Group A consisted of MMVD predisposed dogs with no 
auscultatory heart murmur and normal echocardiogram, group B1 of dogs with 
mild signs of MMVD, group B2 of dogs with moderate signs of MMVD, and 
group C of dogs with MMVD and congestive heart failure (Reimann et al., 
2016).   
C-reactive protein concentrations were measured with the hsCRP assay in 
duplicate in one run. Prior to using the hsCRP test, samples were confirmed to 
have CRP concentration < 30 mg/l to avoid error from prozone effect (Reimann 
et al., 2016). 
Statistical tests included the Kruskal-Wallis test to assess differences in CRP 
concentration, age and weight between dogs in the different ACVIM groups. If 
significant (p < 0.05), pair-wise comparisons between groups were performed 
using the Mann-Whitney U test. Significance level was set to p < 0.008, using 
Bonferroni adjustment for multiple comparisons. 
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Multiple regression analysis was performed to evaluate associations between 
CRP concentration (response variable) and the explanatory variables ACVIM 
group, age, sex, body weight, systolic blood pressure, serum storage time, sub-
study, and breed (Cavalier King Charles Spaniel/other breed) (Reimann et al., 
2016). Backward step-wise elimination of explanatory variables based on p 
values was performed, until only variables with p < 0.05 remained in the model.  
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7 Results and discussion 
7.1 Method validation studies (Paper I and II) 
Results from the validation studies of the cCRP and hsCRP assays are 
summarized in Table 3. Slightly different validation protocols were used for the 
two methods.  For example, the LoB and LoD were not determined for the cCRP 
test, because this was judged to be irrelevant for an assay intended for measuring 
markedly increased CRP concentrations in dogs with systemic inflammation. 
While both inter- and intra-assay variation were thoroughly evaluated for the 
cCRP assay, determination of intra-assay variation was prioritized for the hsCRP 
assay considering that research samples are preferably analysed in one run.  
 
Table 3. Results from method validation studies of the canine-specific C-reactive protein assay 
(cCRP) and the canine-specific high-sensitivity C-reactive protein assay (hsCRP). 
Parameter cCRP hsCRP 
Measurement range 
Intra-assay CV 
Inter-assay CV 
Limit of Blank 
Limit of Detection 
Limit of Quantification 
Presence of relevant prozone effect 
Recovery after spiking 
Interference from haemoglobin/triglycerides 
Storage stability at room temperature and 4°C 
Acceptable agreement in method comparison study 
6.8-1200 mg/l1 
≤  1.7% 
≤  1.9% 
ND 
ND 
6.8 mg/l 
No 
116-123% 
No 
≥ 14 days  
No 
 
0.5-30 mg/l 
≤  2.7% 
≤  3.0% 
0.10 mg/l 
0.22 mg/l 
0.50 mg/l 
Yes 
114-117% 
Yes 
ND 
No 
1Dilutions required for samples with CRP concentrations > 300 mg/l. 
CV = coefficient of variation 
ND = not determined 
 
The imprecisions of both the cCRP and hsCRP assay were lower than the 
maximal allowable imprecision based on biological variation (12%), (Kjelgaard-
Hansen et al., 2003c), and similar or lower compared to imprecisions reported 
for other CRP assays (Klenner et al., 2010; Parra et al., 2006; Kjelgaard-Hansen 
et al., 2003a; Kjelgaard-Hansen et al., 2003b). The LoQ for the cCRP assay, 6.8 
mg/l, was below the locally established clinical decision limit of 20 mg/l which 
was considered sufficient for clinical use. The LoQ of the hsCRP assay was 0.5 
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mg/l, which was below the mean CRP concentrations measured in healthy dogs 
with this assay (Reimann et al., 2016, Paper II and III).  
The presence of possible prozone effect was investigated both for the cCRP 
and hsCRP assay. With the cCRP test, a spiked sample with CRP concentration 
of approximately 1200 mg/l was correctly reported to have CRP concentration 
> 300 mg/l by the assay, and it was concluded that no relevant prozone effect 
was present. The  tested concentration of 1200 mg/l was well above the highest 
CRP concentration measured in a routine sample at the Clinical Pathology 
Laboratory, University Animal Hospital, SLU, about 800 mg/l (data not shown). 
Therefore, an acceptable safety zone was considered to be present.  
The hsCRP assay, on the other hand, did report erroneuos CRP results due to 
prozone effect. For example, a sample with CRP concentration of 228 mg/l was 
reported to have CRP concentration 20 mg/l by the hsCRP test, instead of being 
correctly reported to have CRP concentration > 30 mg/l. This prozone effect 
occurred because the amount of CRP in this sample was too high in relation to 
the amount of anti-canine CRP antibodies in the reagent, preventing  successful 
formation of antigen-antibody complexes (Figure 6). Because of the prozone 
effect, it is strongly recommended not to use the hsCRP as a single test. Instead, 
CRP concentration should first be measured with an assay not affected by 
prozone effect, followed by re-analysis with the hsCRP test only for samples 
with low CRP concentrations. 
 
 
 
 
Figure 6. Schematic illustration of prozone effect. The amount of CRP (blue structures) in the 
sample is inappropriately high in relation to the amount of anti-canine CRP antibodies, which 
prevents successful formation of antigen-antibody complexes.   
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No interfering effect from haemolysis or lipemia was detected with the cCRP 
test, which is important considering that these changes are commonly present in 
samples submitted for routine analysis. Interference from lipemia was tested by 
adding a fat emulsion (Intralipid®) to canine serum samples, which is a widely 
used and feasible approach. However, transference of results from the 
experimental setting to naturally lipemic samples can be questioned, because the 
particle sizes of the lipids are different in the commercial fat emulsion compared 
to what is encountered in vivo (Nikolac, 2014). When samples from dogs in the 
clinical studies were analysed with the hsCRP assay, there were occasional 
lipemic samples in which CRP concentrations were not possible to measure. 
Instead, the instrument reported that the absorbance of the sample exceeded the 
upper optical limit. The explanation for this error message was that the turbidity 
of the lipemic sample was too high to allow for enough light to be transmitted 
through the solution. The triglyceride concentrations in the naturally lipemic 
samples were lower than the triglyceride concentration in the lipemic samples 
used in the interference studies (data not shown). It was concluded that, despite 
the fact that experimentally induced lipemia had no or only mild interfering 
effect, this could not be granted in naturally lipemic samples. The same 
conclusion was drawn in another study comparing the effect of Intralipid® and 
natural lipemia (Bornhorst et al., 2004). Because of this, high-speed or ultra-
centrifugation of lipemic samples is recommended prior to performing CRP 
measurements. This is important particularly for the hsCRP assay, which is more 
susceptible to interfering substances because of the larger sample volume used 
with this test.  
CRP was stable at room temperature for at least two weeks, which is relevant 
information for veterinarians sending samples to referral laboratories for CRP 
analysis. For long-term storage of CRP samples, freezing at -80°C can be 
recommended; at this temperature, human CRP was reported to be stable for 11 
years (Doumatey et al., 2014).  
Bias could not be assessed in the validation studies, due to the lack of 
reference material or a gold standard method for accurate determination of 
canine CRP. Therefore, the method comparison studies did not aim to determine 
true bias, but rather to evaluate whether different assays could be used 
interchangeably. The results showed that this was not possible, and it is thus 
necessary to establish reference intervals and clinical decision limits for each 
individual method.  
In the method validation studies performed in this thesis, analytical quality 
requirements were set based on data on biological variation in healthy dogs. 
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However, the relevance of using such data for setting quality requirements for 
CRP tests can be questioned, considering that healthy animals have much lower 
CRP concentrations compared with dogs with systemic inflammation  
(Antonsen, 1994). An increase in absolute CRP concentration of 1 mg/l would 
represent a 100% increase if the original CRP concentration was 1 mg/l, but only 
a 1% increase if the original CRP concentration was 100 mg/l. Studies for 
determining analytical quality goals based on criteria other than biological 
variation needs to be performed for canine CRP, to obtain more relevant data for 
this purpose. 
After successful termination of the method validation studies in this project, 
the cCRP and hsCRP assays were applied on samples from clinical research 
studies. The performance of the assays could thus be assessed over time when 
analysing samples from a large number of dogs, using different reagent batches 
and with analyses performed under various conditions. This provided an 
opportunity to identify problems that went unnoticed in the validation studies, 
such as the differences in interfering effect between naturally and experimentally 
induced lipemia. Furthermore, precision and dilution experiments confirmed 
stable performance across batches (data not shown). It is required that an assay 
is used over an extended period of time, during different times of the year, is 
operated by different persons and with different reagent batches, for the 
laboratory to conclude that they have a stable working assay. This can now be 
considered to be accomplished for both the cCRP and hsCRP test at the Clinical 
Pathology Laboratory, University Animal Hospital, SLU.  
In conclusion, the method validation studies showed that the cCRP and 
hsCRP assays met most of the predefined quality criteria. Using these two novel 
assays, canine CRP could be reliably measured in the range of 0.5-1200 mg/l, 
which corresponds to the CRP concentrations expected to occur in dogs. 
 
7.2 C-reactive protein as a quantitative marker of systemic 
inflammation  
7.2.1 C-reactive protein in dogs envenomed by Vipera berus (Paper III)  
Viper venom has proteolytic, fibrinolytic, anticoagulant and phospholipase A2 
effects, causing tissue damage and inflammation in the envenomed animal 
(Goddard et al., 2011). Increased CRP concentrations have previously been 
reported in dogs envenomed by V. berus (Langhorn et al., 2013b), and were 
found also in the current study where the median (IQR) CRP concentration on 
Day 2 was 68 (36-101) mg/l in 57 envenomed dogs. There was a moderate 
positive correlation between degree of oedema and CRP concentration (rs=0.45, 
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p=0.01). It has previously been reported that CRP concentrations reflected well 
the extent of local tissue damage in experimental settings (Kjelgaard-Hansen et 
al., 2013; Otabe et al., 2000). In these studies, degree of tissue injury could be 
determined with high accuracy. Such exact quantification was not possible in the 
current study, where local inflammation was assessed by various veterinarians 
measuring the circumference of the bitten body parts. Despite this, a positive 
correlation between degree of oedema and CRP concentration was found as 
hypothesized.   
The fact that CRP is a quantitative marker of systemic inflammation is 
advantageous both in the clinical setting and in research; for example, 
measurement of CRP concentration has been used to grade and compare the 
inflammatory response after different types of surgery (Liu et al., 2013; 
Michelsen et al., 2012; Freeman et al., 2010). The next section, describing CRP 
concentrations before and after ovariohysterectomy in dogs with pyometra, 
constitutes an example where measurement of CRP was applied to quantify a 
systemic inflammatory response.   
 
7.2.2 C-reactive protein in dogs with pyometra undergoing ovariohysterectomy 
Twenty-nine dogs were included in the study investigating degree of systemic 
inflammation in dogs with pyometra undergoing ovariohysterectomy. The dogs 
were of 12 different breeds, with a median (IQR) age of 7.5 (5-12) years and 
median (IQR) weight of 29 (21-39) kg. No dog was excluded because of 
concurrent disease.  
The median (IQR) pre-operative CRP concentration was 254 (177-364) mg/l. 
The day after surgery, median (IQR) CRP concentration had decreased 
significantly to 199 (165-271) mg/l (p < 0.001). Of the 29 dogs, 22 (76%) had 
decreased CRP concentration the day after surgery compared to the pre-
operative CRP concentration. The conclusion was that the removal of the 
inflamed uterus had a larger impact on degree of systemic inflammation, 
compared to additional tissue trauma caused by surgery. It would not have been 
possible to draw this conclusion based on other routinely available measures of 
systemic inflammation, such as the leukocyte count or body temperature. The 
leukocyte numbers were generally increased the day after ovariohysterectomy, 
explained by the fact that neutrophils were no longer consumed in the uterus 
(data not shown). Measurement of body temperature was of limited value for 
monitoring systemic inflammation, because most of the dogs were treated with 
NSAID which has anti-pyretic effect. These findings illustrate the benefits of 
using CRP concentration as a marker for quantifying systemic inflammation.   
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Post-operative complications were reported in two of the dogs, and included 
one case of post-operative infection and one case of acute gastroenteritis. 
Repeated measurements of CRP concentration have previously been shown to 
be useful for detecting post-operative complications in dogs undergoing 
ovariohysterectomy (Dabrowski et al., 2009). In the current study, data about 
complications were not collected in a standardized way and it was therefore not 
possible to evaluate the efficacy of CRP as a diagnostic test for this purpose. 
However, it was notable that the most pronounced increases in CRP 
concentrations the day after surgery compared to pre-operative levels were 
found in the two dogs with reported complications.  
Previous studies of the effects of ovariohysterectomy on CRP concentration 
in dogs with pyometra have shown diverging results. Two studies reported on 
an increase in mean CRP concentration the day after ovariohysterectomy  
(Dabrowski et al., 2009; Dabrowski et al., 2007), whereas another study found 
the opposite result (Yuki et al., 2010). There are several possible explanations 
for the diverging results. The use of different surgical techniques could not be 
excluded with certainty, although a similar open approach ovariohysterectomy 
was presumably performed in all of the experiments (Yuki et al., 2010; 
Dabrowski et al., 2009; Dabrowski et al., 2007). The severity of pyometra may 
have differed between studies, as well as medical treatment strategies. It has also 
been suggested that surgeon experience and use of anaesthetics may affect 
degree of post-operative inflammation (Liao et al., 2014; Michelsen et al., 
2012). This is something that needs to be further studied, so that optimal 
treatment strategies can be established for dogs with pyometra undergoing 
ovariohysterectomy.  
 
7.3 C-reactive protein as a diagnostic test 
7.3.1 Measurement of C-reactive protein concentration for discriminating 
between suppurative arthritis and osteoarthritis in dogs (Paper IV) 
Thirty-one dogs with suppurative arthritis and 34 dogs with OA were included 
in the study. Median (IQR) CRP concentrations in the two groups were 107 (43-
145) mg/l and 0.73 (< 0.5-2.45) mg/l, respectively. In the logistic regression 
analysis, the final model included log2 CRP (p=0.03, OR 7.37) and sex (p=0.12, 
OR 0.005) as explanatory variables. The interpretation of OR for log2CRP was 
that for a doubling of serum CRP concentration, the odds of having suppurative 
arthritis increased with 7.37. Although sex remained as an explanatory variable 
in the final model, it was not considered to be of clinical importance.  
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In the ROC curve analysis, the AUC (95% CI) was 0.99 (0.97-1.00). When 
comparing CRP results to the previously established clinical decision limit of 20 
mg/l, there were two false negative and one false positive result among the 65 
dogs. Based on these findings, it was concluded that CRP concentration 
discriminated well between dogs with suppurative arthritis and dogs with OA.  
The study on dogs with joint disease was designed according to the STARD 
criteria, as recommended (Christopher, 2007; Bossuyt et al., 2004). Although 
such reports are important to enhance evidence-based use of diagnostic tests, 
they are not sufficient. It remains to be investigated whether measurement of 
CRP actually makes a difference for outcome, or other relevant factors, in a 
clinical setting. In dogs with joint disease, it would be interesting to determine 
whether knowledge about CRP concentration could improve decision making 
regarding diagnostic interventions. Especially in a dog with known OA, a sudden 
increase in pain and lameness could be attributed to a worsening of the 
underlying disease. However, dogs with OA may be predisposed for septic 
arthritis, which constitutes an important differential diagnosis (Clements et al., 
2005). While arthrocentesis is not required in a dog with OA, it is crucial for 
diagnosis of septic arthritis, and knowledge on CRP concentration might be 
valuable for determining which patients that should undergo arthrocentesis. It 
could be argued that a physical examination is usually sufficient to adequately 
distinguish between a dog with suppurative arthritis and OA (Foster et al., 2014), 
making measurement of CRP concentration superfluous. However, clinical signs 
may be unspecific (Rondeau et al., 2005; Jacques et al., 2002) and physical 
examination is subjective, in contrast to CRP which is an objective marker and 
thus not biased by level of clinical expertise.  
 
7.3.2 C-reactive protein concentration as a test for diagnosing post-operative 
infections after orthopaedic surgery 
In the study of dogs undergoing orthopaedic surgery, in total 15 dogs with 
suspected post-operative infections were included (Figure 7). One dog was 
excluded because of inconclusive test result. The remaining dogs were of 10 
different breeds, with median (IQR) age  and weight of 4 (3-6) years and 34 (23-
42) kg, respectively. Surgical procedures included tibial plateau leveling 
osteotomy (n=4), carpal arthrodesis (n=4), fracture surgery (n=2), lateral suture 
stabilisation after cruciate ligament rupture (n=2), ulnar osteotomy (n=1), and 
arthroscopy (n=1). Dogs were sampled on day 20-360 after surgery. Seven dogs 
were classified as infected based on positive bacterial culture result (n=2), 
positive bacterial culture result and cytological signs of infection (n=3), positive 
culture result and radiographic findings suggestive of osteomyelitis (n=1), and 
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cytological signs of infection (n=1). The remaining dogs were classified as not 
infected (n=7). 
Four of the infected dogs had CRP concentrations below the clinical decision 
limit for CRP, 20 mg/l, and two dogs with no infection had CRP concentration 
> 20 mg/l (Figure 7 and 8). There was no significant difference in CRP 
concentration between dogs with infections and dogs with non-infectious 
complications (p=0.44). 
 
 
 
 
 
 
Figure 7. Flow diagram of dogs with suspected post-operative infections. Reference tests for 
diagnosing infection included bacterial culture, cytological examination, and/or radiographic 
examination. CRP=C-reactive protein 
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Figure 8. Individual value plot of serum C-reactive protein (CRP) concentrations in dogs with 
suspected post-operative infections after orthopaedic surgery. Dogs were classified as infected 
(n=7) or not infected (n=7). The horizontal line represents the locally established clinical decision 
limit of CRP for diagnosing systemic inflammation, 20 mg/l. 
  
Seven control dogs were sampled between day 20 and 65 days after surgery. 
The control dogs were of 7 different breeds, with median (IQR) age and weight 
of 4 (1-9) years and 29 (10-47) kg, respectively. Surgical procedures in the 
control dogs included tibial plateau leveling osteotomy (n=4), lateral suture 
stabilisation after cruciate ligament rupture (n=2), and fracture surgery (n=1). 
All control dogs had CRP concentration < 6.8 mg/l, which was significantly 
lower compared to the other group of dogs with suspected infections (p=0.003). 
However, this finding was considered to be of limited interest in a clinical 
setting, where the problem is to distinguish between dogs with infectious and 
non-infectious complications rather than between dogs with complications and 
dogs with uneventful recoveries.  
The plausible explanation for the poor performance of CRP for detecting 
post-operative infections was that these infections did not always elicit a 
systemic inflammatory response. This is similar to conditions such as mild 
sterile subcutaneous inflammation (Bauer et al., 2012) and inflammation in the 
central nervous system (Vestergaard et al., 2013), where signs of local 
inflammation were present without a simultaneous increase in CRP 
concentration. C-reactive protein is a marker of systemic inflammation only, and 
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presence of local inflammation cannot be excluded based on a low CRP 
concentration. The reason for the increased CRP concentrations found in two 
dogs that were not infected was not determined, but traumatic injury was a 
possibility.  
No specific diagnostic tests were performed in the control dogs to exclude 
presence of infection, which is a limitation of the study. The reason for not 
collecting samples for bacterial culture and cytology in the control dogs was that 
this would have required invasive procedures in apparently healed areas, with a 
minor but still relevant risk of inducing complications. In the review of the dogs’ 
medical records, none of the control dogs was reported to suffer from a post-
operative complication during the first month after sampling. Therefore, 
erroneous inclusion of infected dogs in the control group was considered less 
likely.  
In conclusion, CRP concentration was not efficient for discriminating 
between dogs with late bacterial infections after orthopaedic surgery and dogs 
with post-operative complications not caused by infection. The likely 
explanation to this finding was that post-operative infections often did not elicit 
a systemic inflammatory response enough to induce an increased CRP 
concentration.  
  
7.4 Application of the high-sensitivity C-reactive protein assay 
on samples from dogs with myxomatous mitral valve 
disease  
A total of 188 dogs were included in the study investigating whether CRP 
concentrations were associated with severity of MMVD (Reimann et al., 2016). 
Dogs with congestive heart failure (group C) had higher CRP concentrations 
compared with dogs in all other groups (Table 4). However, there was no 
difference in CRP concentration between dogs without MMVD and dogs with 
mild to moderate MMVD without congestive heart failure. There were 
statistically significant differences between groups for age and body weight 
(Table 4), but these variables were not significant in the multiple regression 
analysis. The final multiple regression model had an adjusted r2 of 0.13, and 
ACVIM group was the only significant explanatory variable (p < 0.001) 
(Reimann et al., 2016).  
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Table 4. Dog characteristics and serum C-reactive protein (CRP) concentration in 188 dogs 
without and with different severities of myxomatous mitral valve disease (MMVD) according to 
American College of Veterinary Internal Medicine (ACVIM) criteria. Median and interquartiles 
are reported. Superscript letters a, b1, b2 and c represents ACVIM group from which there was a 
statistically significant difference. Modified from Reimann et al (2016).   
ACVIM group A  B1 B2 C 
Number of dogs 58 56 38 36 
Sex (male/female) 36/22 36/20 17/21 9/27 
Age (years) 5.5 (4.2;6.8)b1,b2,c 6.9 (6.2;10.0)a,c 8.4 (7.1;9.6) a,c 10.8(9.0;11.7)a,b1,b2 
Body weight (kg) 8.6 (7.6;9.7) b1,b2,c 9.8 (8.0; 10.7)a 10.0 (8.5;11.0)a 10.4 (8.2;12.3)a 
CRP (mg/l) 0.97  
(<0.5; 1.97)c 
0.78  
(<0.5; 1.73)c 
0.60 
(<0.5; 1.23)c 
2.65  
(1.09; 5.09)a,b1,b2 
 
 
Although there was a statistically significant difference in CRP concentration 
between dogs with congestive heart failure and dogs with milder forms of 
MMVD, CRP concentrations were low and overlapping. This was expected 
based on results from previous investigations (Cunningham et al., 2012; 
Ljungvall et al., 2010; Rush et al., 2006), and the current study did not aim to 
evaluate CRP as a diagnostic test in these patients. Instead, the research was 
performed to map the pathophysiological changes occurring in dogs with 
MMVD. Traditionally, MMVD has been considered to be a non-inflammatory 
disease. However, up-regulation of genes involved in inflammation, and 
increased concentrations of pro-inflammatory cytokines, have been reported in 
late stages of canine MMVD (Zois et al., 2012; Oyama & Chittur, 2006). In 
human beings, a positive correlation between cardiovascular disease and CRP 
concentration is well-described (Hingorani et al., 2009; Ridker et al., 2009; 
Ridker et al., 2004). In dogs, on the other hand, studies on CRP concentrations 
in heart disease have shown diverging results. Myxomatous mitral valve disease 
was reported to be associated with increased CRP concentrations in one study 
(Rush et al., 2006), whereas another study did not support this finding (Ljungvall 
et al., 2010). Similarly, information on CRP concentrations in dogs with 
congestive heart failure has been inconclusive (Cunningham et al., 2012; Rush 
et al., 2006). Several possible explanations exist for the inconsistency in reported 
results.   
First, not all studies adjusted for baseline variables such as age, sex and breed 
when analysing CRP data. Although these factors are probably irrelevant when 
studying the marked increased CRP concentrations present in dogs with 
systemic inflammatory disease, it is possible that they influence results when 
investigating minor changes at low CRP concentrations.  
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Second, presence of underlying diseases that might affect CRP 
concentrations was not excluded with certainty in the different studies. Low-
grade inflammatory conditions such as osteoarthritis and periodontitis have been 
associated with mildy increased CRP concentrations (Yu et al., 2010; Hurter et 
al., 2005), and these diseases frequently occur in dogs reported to be healthy by 
their owners (Hillström et al., 2015). Such conditions may be difficult to detect 
on physical examination, and will not be identified by performing routine 
haematology and biochemistry testing. It cannot be excluded that presence of 
underlying diseases, not necessarily affecting different populations to the same 
extent, may have biased interpretation of CRP results.   
Finally, the discrepancy between studies could be explained by the use of 
analytical assays with low precision. Measurements of CRP concentrations in 
research have most commonly been performed with ELISA tests, where a 
limited  number of samples can be analysed on a single plate. When several 
ELISA plates are used for CRP measurements, an inter-assay variation due to 
plate differences will inevitably be introduced. The reported inter-assay 
variation for samples with low CRP concentrations was reported to be up to 26% 
for a commercial ELISA commonly used in research (Kjelgaard-Hansen et al., 
2003b). This high imprecision may mask minor changes in CRP concentrations 
that are of interest to study. Moreover, if study samples from different groups of 
dogs are not placed randomly over the plates, erroneous conclusions could be 
drawn because of plate differences. One of the greatest advantages with using 
an automated high-sensitivity CRP assay is that inter-assay variation can be 
limited. In the current study of CRP concentration in dogs with MMVD, all 188 
samples were analysed in duplicate in one single run. The reported intra-assay 
variation for the hsCRP assay was ≤  2.7% (Paper II), which was confirmed by 
calculating intra-assay variation of the duplicate measurements of the study 
samples (data not shown). The high analytical precision makes it possible to 
detect minor changes in CRP concentrations that might otherwise have gone 
unnoticed had an assay with lower precision been used.  
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8 Conclusions 
 
 Two fully automated, canine-specific CRP assays, where of one was 
a high-sensitivity CRP test, were validated. The performance of the 
assays met the pre-defined quality requirements. Using these assays, 
canine CRP could be reliably measured in the concentration range 
of 0.5-1200 mg/l.   
 
 C-reactive protein concentration in dogs envenomed by Vipera 
berus was positively correlated to degree of oedema. This finding 
supports the suitability of using CRP as a quantitative marker of 
systemic inflammation in dogs.   
 
 C-reactive protein concentration was useful for quantifying the 
degree of systemic inflammation in dogs with pyometra undergoing 
ovariohysterectomy. The median CRP concentration decreased the 
day after surgery compared with pre-operative levels, indicating that 
the removal of the inflamed uterus had a greater impact on systemic 
inflammation compared with the additional tissue trauma caused by 
surgery in most of the dogs.  
 
 CRP concentration discriminated well between dogs with 
suppurative arthritis and osteoarthritis, suggesting that CRP has the 
potential to be a valuable diagnostic marker in dogs with joint 
disease.   
 
 CRP concentration was not efficient for diagnosing late post-
operative infections in dogs after orthopaedic surgery. These 
infections often caused inflammations that were purely local, and 
therefore could not be detected by measuring CRP which is a marker 
of systemic inflammation.  
 
 Congestive heart failure in dogs with myxomatous mitral valve 
disease was associated with significant, but very mild increased CRP 
concentrations, indicating that inflammation might be involved in 
the pathogenesis of this condition. The availability of an automated 
hsCRP test enabled measurement of the 188 study samples in one 
single run, avoiding imprecision caused by inter-assay variation.  
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9 Concluding remarks and future 
perspectives 
It has been proposed that diagnostic tests should be subjected to clinical trials 
similar to what therapeutic agents undergo, to ensure evidence-based use of them 
(Kjelgaard-Hansen & Jacobsen, 2011; Ransohoff, 2007; Zweig & Robertson, 
1982). A series of step-wise investigations has been recommended (Table 5) 
(Kjelgaard-Hansen & Jacobsen, 2011). The first step (Phase I) includes method 
validation, as availability of practicable assays with acceptable performance is a 
prerequisite for successful introduction of a new diagnostic test. In the next step 
(Phase II), the overlap performance is investigated where analyte concentrations 
in healthy subjects and in subjects affected by the condition of interest are 
compared. The idea is that if the test does not distinguish well between these two 
groups, it will not be valuable as a diagnostic marker. Failure at this step will 
prevent further, costly, investigations being initiated (Kjelgaard-Hansen & 
Jacobsen, 2011).  
The capability of a test to discriminate between healthy and diseased animals 
does not automatically imply that it is a diagnostically useful test. Premature 
introduction of new diagnostic methods, as well as overestimation of test 
performance, will occur if relying on overlap performance data for judging the 
efficacy of a diagnostic marker (Ransohoff, 2007). Once it has been concluded 
that a test can distinguish between diseased and healthy individuals, it is 
therefore necessary to continue with studies investigating test performance in a 
clinical setting (Phase III). Recommended guidelines on how to conduct and 
report such studies should be followed, in order to ensure transparency of results 
(Bossuyt et al., 2004). 
The last, most resource-demanding step is to evaluate whether the use of a 
test has an impact on patient outcome or other relevant parameters (Phase IV). 
The question is whether patients that undergo the test fare better than similar 
patient not taking it, i.e. if using the test improves survival, shortens treatment 
time, saves expenses, or provides other advantages compared to existing 
diagnostic methods.  
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Table 5. Phases in the validation of a diagnostic test. Modified from Kjelgaard-Hansen & Jacobsen 
(2011). 
Phase Investigation Description 
I Analytical performance Method validation study and investigation of 
applicability 
II Overlap performance Measuring analyte concentration in healthy animals 
and animals affected by the condition of interest 
III Clinical performance Evaluating performance of the test in a clinical 
setting 
IV Outcome and usefulness Evaluating if performing the test has beneficial 
effects on outcome, or other relevant parameters 
 
So, where should canine CRP be placed in this process of marker validation? 
As shown in the current thesis (Paper I and II), functional assays for measuring 
canine CRP are available, which means that Phase I requirements are fulfilled 
(Table 5). Phase II studies have shown that CRP efficiently discriminates 
between dogs with and without systemic inflammation (Christensen et al., 2014; 
Nakamura et al., 2008; Caspi et al., 1987). C-reactive protein has become a well-
established inflammatory marker in dogs, even used in research to define 
presence of, or quantify, systemic inflammation (Liao et al., 2014; Langhorn et 
al., 2013a; Langhorn et al., 2013b; Liu et al., 2013; Michelsen et al., 2012; 
Freeman et al., 2010).  
Studies in a clinical setting (Phase III studies) have indicated that CRP is also 
a valuable diagnostic test. Repeated CRP measurements can be used to follow 
response to treatment and for judging prognosis, as previously described. In dogs 
with similar clinical findings, CRP concentration can discriminate between 
plausible differential diagnoses such as pyometra and mucometra (Fransson et 
al., 2004), bacterial pneumonia and other respiratory diseases (Viitanen et al., 
2014), and suppurative arthritis and OA (Paper IV). Probably there are other 
clinical situations where knowledge on CRP concentration is helpful for 
establishing an aetiologic diagnosis, as long as the CRP result is interpreted in a 
specific, well-defined context.  
The final step, to investigate whether measurement of CRP affects outcome 
(Phase IV), still awaits to be realized. Although such studies are resource-
demanding, they are crucial to conduct to improve the use of CRP as a diagnostic 
test. There are numerous possible study designs that could be used. One example 
would be to let veterinarians judge clinical cases first without, and then with, 
knowledge of CRP concentration, to see whether the additional information 
allowed for a more correct interpretation of the case. Another relevant study 
would be to randomly measure CRP in only part of the dogs admitted to 
veterinary care, and evaluate whether outcome was improved in this group. In 
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hospitalised patients, it would be interesting to investigate if repeated CRP 
measurements enabled more effective decision making regarding whether a dog 
should be discharged or not. Conducting this type of Phase IV studies will be of 
great importance for evidence-based use of CRP as an inflammatory marker, and 
the fact that automated canine-specific CRP assays are now available should 
facilitate the research.    
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10 Populärvetenskaplig sammanfattning 
C-reaktivt protein (CRP) är ett akutfasprotein vars koncentration i blodet stiger 
kraftigt vid inflammatoriska tillstånd hos hund. Koncentrationen av CRP är hög 
så länge hunden har en aktiv inflammation, men sjunker snabbt när effektiv 
behandling sätts in. Detta gör CRP till ett värdefullt test både för att upptäcka 
och följa inflammatoriska sjukdomar hos hundar. C-reaktivt protein har också 
fördelen att det inte påverkas av om hunden behandlas med till exempel kortison 
eller smärtstillande mediciner, vilket är viktigt eftersom dessa läkemedel ofta 
ges som behandling vid inflammatoriska sjukdomar. Vidare är CRP ett mycket 
stabilt protein, vilket förenklar provtagning och provhantering. Ett problem har 
dock varit att det saknats analysmetoder för att snabbt och säkert mäta CRP hos 
hund. Koncentrationen av CRP i blodet hos hundar har oftast analyserats med 
metoder utvecklade för att mäta människans CRP, som visserligen liknar 
hundens CRP men inte är identiskt med det. Därför fungerar metoder framtagna 
för människor mindre bra för hundprover. Huvudsyftet med projektet som 
beskrivs i denna avhandling var att ta fram nya, automatiserade tester anpassade 
för att mäta CRP specifikt hos hund.  
I ett första steg i detta forskningsrpojekt utvecklades en metod som kunde 
mäta de kraftigt förhöjda nivåer av CRP som förekommer hos hundar med 
inflammatoriska sjukdomar. Syftet var att detta test skulle kunna användas 
rutinmässigt av kliniskt verksamma veterinärer för att upptäcka och följa 
inflammation hos sjuka hundar. I ett andra steg utvecklades en så kallad hög-
känslig CRP-metod för att möjliggöra exakta mätningar av CRP vid mycket låga 
koncentrationer. Sådana mätningar är av intresse för att undersöka tillstånd som 
tros ha samband med låggradig, långvarig inflammation, exempelvis fetma. Hos 
människa är det visat att denna typ av låggradig inflammation är skadlig, och det 
behövs forskning för att undersöka om detsamma gäller hundar.   
Omfattande tester av de båda nya CRP-metoderna genomfördes i syfte att 
säkerställa att de fungerade tillfredsställande. Resultaten redovisas i två 
publikationer som är inkluderade i avhandlingen. I artiklarna finns detaljerad 
information om hur de nya metoderna fungerar och hur de kan användas. Bland 
annat beskrivs det hur CRP analyseras direkt i ett stort analysinstrument, vilket 
innebär att mätningen är helt automatiserad. Detta möjliggör tillförlitliga och 
snabba analyssvar, vilket är en fördel både i klinisk verksamhet och inom 
forskning.  
Ett ytterligare mål med doktorandprojektet var att utföra studier som syftade 
till att öka kunskapen om CRP som ett diagnostiskt test hos hund. I avhandlingen 
beskrivs bland annat hur analys av CRP var effektivt för att särskilja hundar som 
hade inflammatorisk ledsjukdom från hundar med artros, som är en sjukdom där 
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ledbrosket gradvis bryts ned. Vid misstanke om inflammatorisk ledsjukdom 
behöver ett prov tas från ledvätskan och ofta krävs behandling med antibiotika 
eller kortison. Vid artros är detta inte nödvändigt, utan hunden kan ofta skickas 
hem på smärtstillande medicin som en första åtgärd. Genom att analysera CRP 
kan veterinären få hjälp i sin bedömning av huruvida en hund med ledsmärta 
mest sannolikt har en inflammation i leden eller artros, vilket påverkar hur 
patienten utreds och behandlas.  
I en studie undersöktes om CRP var ett bra test för att upptäcka infektioner 
hos hundar som opererats i skelett och leder. Ibland uppstår infektioner veckor 
till månader efter sådana ingrepp och det är viktigt att behandla dessa för att 
förhindra allvarligare komplikationer. Analys av CRP var dock inte effektivt för 
att bedöma huruvida det fanns en infektion eller inte. Förklaringen var att de 
infekterade hundarna ofta hade lokala inflammationer som var lindriga och 
tydligt avgränsade, dvs inflammationen var inte tillräckligt omfattande för att 
orsaka en stegring av CRP i blodet. Det innebär att ett lågt CRP-värde inte 
utesluter infektion hos denna patientgrupp.  
Ytterligare två studier som finns beskrivna i avhandlingen handlar om CRP 
hos ormbitna hundar och hos hundar med livmoderinflammation. Resultaten 
visade att CRP var en användbar markör för att upptäcka och följa inflammation 
vid dessa tillstånd.  
Sammanfattningsvis finns nu automatiserade metoder speciellt utvecklade 
för att mäta CRP hos hund tillgängliga. Detta är en stor fördel både inom 
djursjukvården och inom forskning och kommer att möjliggöra ett mer effektivt 
användande av CRP som diagnostiskt test i framtiden.     
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